ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Shire Strengthens Rare Diseases With Dyax Buy

by Lisa M. Jarvis
November 9, 2015 | APPEARED IN VOLUME 93, ISSUE 44

Shire will pay roughly $5.9 billion to acquire the biotech firm Dyax. The deal will deepen Shire’s roster of treatments for hereditary angioedema (HAE), a rare, genetic immune system disorder. Dyax adds the approved HAE drug Kalbitor, and DX-2930, a plasma kallikrein inhibitor that is expected to start Phase III trials in HAE later this year. Shire, which already markets the HAE treatment Cinryze, says DX-2930 could generate annual sales of up to $2 billion. Shire claims that the deal for Dyax will not disrupt its ongoing pursuit of the specialty pharmaceuticals firm Baxalta, which this summer rejected an unsolicited $30 billion bid from Shire.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment